Similar Posts
Scientists See New Hope for Restoring Vision With Stem Cell Help
Human-derived stem cells can spontaneously form the tissue that develops into the part of the eye that allows us to see, according to a study published by Cell Press in the 5th anniversary issue of the journal Cell Stem Cell. Transplantation of this 3D tissue in the future could help patients with visual impairments see…
Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies
Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases. Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet…
New drug candidate is promising therapeutic option for angiogenic retinal diseases
A research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal…
Topical Dorzolamide-Timolol With Intravitreous Anti–Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration
Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration (AMD) and incomplete response to anti-vascular endothelial growth factor (VEGF) therapy, according to a study published online Feb. 25 in JAMA Ophthalmology. Jayanth Sridhar, M.D., from the Thomas Jefferson University in Philadelphia, and colleagues…
SDM Photocoagulation Superior to Intravitreal Injections of BCZ in the Treatment of CSC
A recent study was conducted to evaluate the treatment of central serous chorioretinopathy (CSC) with either subthreshold diode laser MicroPulse (SDM) or intravitreal bevacizumab (BCZ). The study was conducted over a period of 10 months and examined 52 eyes of 52 patients with (a) treatment with SDM at the active leakage site guided by fluorescein…
Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics
Avalanche Biotechnologies, Inc. (AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics. “The new management team is focused on applying our extensive clinical development expertise to advance the company’s gene therapy programs into the clinic. We intend on dosing our first patients for A1AT deficiency by the end of this year…